|
|||||
|
|
Anthracycline cardiotoxicity. |
|
| Authors: | Paul G Horan Mary Frances McMullin Pascal P McKeown |
| Affiliation: | 1 Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, Northern Ireland, UK 2 Department of Haematology, Queen's University Belfast, Northern Ireland, UK 3 Department of Medicine, Institute of Clinical Science, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, Northern Ireland, UK |
| Abstract: | Anthracycline drugs have been widely used as chemotherapeuticagents against a range of cancers, including sarcomas, carcinomas,leukaemias, and lymphomas. However, cardiotoxic effects, inparticular the development of cardiomyopathy, have limited theirclinical use. The observation of dose-dependent cardiotoxicityhas resulted in a recommended empirical dose limit of 450 mg/m2of body surface area. Age, gender, pre-existing heart disease,hypertension, and mediastinal irradiation have also been implicatedas factors contributing to the development of doxorubicin-associatedcardiomyopathy. However, cardiotoxicity may still occur at relativelylow levels of drug administration, even in individuals withno additional risk factors, and the onset may be delayed bymany years.1 More recently, the use of trastuzumab, a monoclonalantibody directed against the HER2 receptor, has been |
| Keywords: | |
| 本文献已被 Oxford 等数据库收录！ | |